TY - JOUR
T1 - BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation
AU - Wang, Lin
AU - Park, Paul
AU - La Marca, Frank
AU - Than, Khoi D.
AU - Lin, Chia Ying
N1 - Funding Information:
The authors gratefully acknowledge funding support provided by National Institutes of Health Grant R01 AR 056649 and the pilot research fund of the Department of Neurosurgery, University of Michigan. The authors also thank Mrs. Holly Wagner for assistance in the preparation of the manuscript and Mr. Martin J. White for flow cytometry.
Publisher Copyright:
© 2014, Springer-Verlag Berlin Heidelberg.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Purpose: We have previously shown that BMP-2 induces bone formation and inhibits tumorigenicity of cancer stem cells (CSCs) in a human osteosarcoma OS99-1 cell line. In this study, we sought to determine whether BMP-2 can similarly induce bone formation and inhibit the tumorigenicity of renal CSCs identified based on aldehyde dehydrogenase (ALDH) activity in renal cell carcinoma (RCC) cell lines and primary tumors.Methods: Using a xenograft model in which cells from human RCC cell lines ACHN, Caki-2, and primary tumors were grown in NOD/SCID mice, renal CSCs were identified as a subset of ALDHbr cells. The ALDHbr cells possessed a greater colony-forming efficiency, higher proliferative output, increased expression of stem cell marker genes Oct3/4A, Nanog, renal embryonic marker Pax-2, and greater tumorigenicity compared to cells with low ALDH activity (ALDHlo cells), generating new tumors with as few as 25 cells in mice.Results: In vitro, BMP-2 was found to inhibit the ALDHbr cell growth, down-regulate the expression of embryonic stem cell markers, and up-regulate the transcription of osteogenic markers. In vivo, all animals receiving a low number of ALDHbr cells (5 × 103) from ACHN, Caki-2, and primary tumor xenografts treated with 30 µg BMP-2 per animal showed limited tumor growth with significant bone formation, while untreated cells developed large tumor masses without bone formation.Conclusions: These results suggest that BMP-2 inhibits the tumor-initiating ability of renal CSCs and induces osseous bone formation. BMP-2 may therefore provide a beneficial strategy for human RCC treatment by targeting the CSC-enriched population.
AB - Purpose: We have previously shown that BMP-2 induces bone formation and inhibits tumorigenicity of cancer stem cells (CSCs) in a human osteosarcoma OS99-1 cell line. In this study, we sought to determine whether BMP-2 can similarly induce bone formation and inhibit the tumorigenicity of renal CSCs identified based on aldehyde dehydrogenase (ALDH) activity in renal cell carcinoma (RCC) cell lines and primary tumors.Methods: Using a xenograft model in which cells from human RCC cell lines ACHN, Caki-2, and primary tumors were grown in NOD/SCID mice, renal CSCs were identified as a subset of ALDHbr cells. The ALDHbr cells possessed a greater colony-forming efficiency, higher proliferative output, increased expression of stem cell marker genes Oct3/4A, Nanog, renal embryonic marker Pax-2, and greater tumorigenicity compared to cells with low ALDH activity (ALDHlo cells), generating new tumors with as few as 25 cells in mice.Results: In vitro, BMP-2 was found to inhibit the ALDHbr cell growth, down-regulate the expression of embryonic stem cell markers, and up-regulate the transcription of osteogenic markers. In vivo, all animals receiving a low number of ALDHbr cells (5 × 103) from ACHN, Caki-2, and primary tumor xenografts treated with 30 µg BMP-2 per animal showed limited tumor growth with significant bone formation, while untreated cells developed large tumor masses without bone formation.Conclusions: These results suggest that BMP-2 inhibits the tumor-initiating ability of renal CSCs and induces osseous bone formation. BMP-2 may therefore provide a beneficial strategy for human RCC treatment by targeting the CSC-enriched population.
KW - Aldehyde dehydrogenase
KW - BMP-2
KW - Cancer stem cells
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84937965099&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937965099&partnerID=8YFLogxK
U2 - 10.1007/s00432-014-1883-0
DO - 10.1007/s00432-014-1883-0
M3 - Article
C2 - 25431339
AN - SCOPUS:84937965099
SN - 0171-5216
VL - 141
SP - 1013
EP - 1024
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 6
ER -